Toxemia  >>  Cubicin (daptomycin)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cubicin (daptomycin) / Merck (MSD)
NCT01287832: Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)

Terminated
4
11
US
Vancomycin, Daptomycin
St. John Health System, Michigan, Henry Ford Health System, Cubist Pharmaceuticals LLC
Bacteremia
01/12
01/12
RENSE, NCT01104662: Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

Terminated
4
92
US
Vancomycin, Daptomycin, Cubicin, Semi-Synthetic Penicillin, SSP, nafcillin, oxacillin, cloxacillin
Cubist Pharmaceuticals LLC
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
06/12
06/12
STOP-NT, NCT01734694: Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

Terminated
4
100
US
Vancomycin, Ceftaroline, Teflaro, Daptomycin, Cubicin, Linezolid, Zyvox
Henry Ford Health System
Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia, Acute Bacterial Skin and Skin Structure Infections
09/12
09/12
NCT01728376 / 2012-003447-29: Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)

Completed
4
82
NA
Daptomycin, Cubicin, Comparator
Cubist Pharmaceuticals LLC
Bacteremia
01/16
01/16

Download Options